1 Department of Anesthesia, Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil.
2 School of Medical Sciences, Lusíada University Center (UNILUS), Santos, SP, Brazil.
3 Department of Orthopedics, Brazilian Institute of Regenerative Medicine (BIRM), Indaiatuba, SP, Brazil.
4 School of Medical Sciences, Ninth of July University (UNINOVE), São Bernardo do Campo, SP, Brazil.
5 School of Medical Sciences, Santa Marcelina University, São Paulo, SP, Brazil.
6 School of Medical Sciences, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil.
7 Regenerative Medicine, Orthoregen International Course, Indaiatuba, SP, Brazil.
8 Clinical Research, Anna Vitória Lana Institute (IAVL), Indaiatuba, SP, Brazil.
9 School of Medical Sciences, Max Planck University Center (UniMAX), Indaiatuba, SP, Brazil.
Review Article
World Journal of Advanced Research and Reviews, 2024, 21(03), 1295-1302
Received on 28 January 2024; revised on 09 March 2024; accepted on 12 March 2024
Cannabis has been used for medicinal purposes more than millennia., further research concerning the potential applications of medicinal cannabis has gained considerable momentum in the medical community. Among the several cannabinoids produced by cannabis leaves, the most notable compounds include Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which act on the endocannabinoid system and play significant physiological roles, such as pain regulation. This manuscript reviews the current knowledge and provides medical evidence about the analgesic potential of medicinal cannabis for chronic pain management. The following databases were searched: MEDLINE, COCHRANE, SCIELO and LILACS. Only randomized controlled trials published within six years were selected. Nine articles met the inclusion criteria for the present review. All nine RCTs reported a significant difference in the reduction in pain intensity; however, only five of the studies reported a significant reduction in pain. The presence of mild-to-moderate adverse events was greater in the intervention groups than in the control group, but these adverse events were well tolerated. The difference in opioid use and other analgesic drugs between the intervention group and the placebo group was not statistically significant. Cannabis-derived compounds promote beneficial effects when administered into patients with chronic pain.
Medicinal cannabis; Chronic pain; Cannabinoids; Analgesia; Pain management
Preview Article PDF
Victoria Pereira Simão, Gabriel Mota Zamariolli Tavares, Gabriel Silva Santos, Alex Pontes de Macedo, Gabriel Ohana Marques Azzini, Rafael Barnabé Domingues, Rodrigo Cuban de Oliveira, Luiza de Sá Narche, Lucas Furtado da Fonseca and José Fabio Lana. The clinical use of cannabinoids for pain. World Journal of Advanced Research and Reviews, 2024, 21(3), 1295-1302. Article DOI: https://doi.org/10.30574/wjarr.2024.21.3.0754